Browse MYH9

Summary
SymbolMYH9
Namemyosin, heavy chain 9, non-muscle
Aliases NMMHCA; NMHC-II-A; MHA; FTNS; EPSTS; nonmuscle myosin heavy chain II-A; DFNA17; myosin, heavy polypeptide 9, ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Cytoplasm, cell cortex Note=Colocalizes with actin filaments at lamellipodia margins and at the leading edge of migrating cells (PubMed:20052411). In retinal pigment epithelial cells, predominantly localized to stress fiber-like structures with some localization to cytoplasmic puncta (PubMed:27331610).
Domain PF00063 Myosin head (motor domain)
PF02736 Myosin N-terminal SH3-like domain
PF01576 Myosin tail
Function

Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. During cell spreading, plays an important role in cytoskeleton reorganization, focal contacts formation (in the margins but not the central part of spreading cells), and lamellipodial retraction; this function is mechanically antagonized by MYH10.

> Gene Ontology
 
Biological Process GO:0000212 meiotic spindle organization
GO:0000226 microtubule cytoskeleton organization
GO:0000768 syncytium formation by plasma membrane fusion
GO:0000910 cytokinesis
GO:0001525 angiogenesis
GO:0001667 ameboidal-type cell migration
GO:0001701 in utero embryonic development
GO:0001767 establishment of lymphocyte polarity
GO:0001768 establishment of T cell polarity
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0006509 membrane protein ectodomain proteolysis
GO:0006909 phagocytosis
GO:0006911 phagocytosis, engulfment
GO:0006949 syncytium formation
GO:0007159 leukocyte cell-cell adhesion
GO:0007163 establishment or maintenance of cell polarity
GO:0007229 integrin-mediated signaling pathway
GO:0007520 myoblast fusion
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008360 regulation of cell shape
GO:0010324 membrane invagination
GO:0010631 epithelial cell migration
GO:0010954 positive regulation of protein processing
GO:0014902 myotube differentiation
GO:0016485 protein processing
GO:0022604 regulation of cell morphogenesis
GO:0030010 establishment of cell polarity
GO:0030048 actin filament-based movement
GO:0030099 myeloid cell differentiation
GO:0030168 platelet activation
GO:0030220 platelet formation
GO:0030224 monocyte differentiation
GO:0031032 actomyosin structure organization
GO:0031532 actin cytoskeleton reorganization
GO:0032796 uropod organization
GO:0032970 regulation of actin filament-based process
GO:0033619 membrane protein proteolysis
GO:0034109 homotypic cell-cell adhesion
GO:0036344 platelet morphogenesis
GO:0042110 T cell activation
GO:0042692 muscle cell differentiation
GO:0043534 blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0045862 positive regulation of proteolysis
GO:0048514 blood vessel morphogenesis
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0050900 leukocyte migration
GO:0051014 actin filament severing
GO:0051146 striated muscle cell differentiation
GO:0051293 establishment of spindle localization
GO:0051295 establishment of meiotic spindle localization
GO:0051321 meiotic cell cycle
GO:0051604 protein maturation
GO:0051640 organelle localization
GO:0051653 spindle localization
GO:0051656 establishment of organelle localization
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070527 platelet aggregation
GO:0070613 regulation of protein processing
GO:0071593 lymphocyte aggregation
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0099024 plasma membrane invagination
GO:1900756 protein processing in phagocytic vesicle
GO:1903046 meiotic cell cycle process
GO:1903131 mononuclear cell differentiation
GO:1903317 regulation of protein maturation
GO:1903319 positive regulation of protein maturation
GO:1903918 regulation of actin filament severing
GO:1903919 negative regulation of actin filament severing
GO:1903921 regulation of protein processing in phagocytic vesicle
GO:1903923 positive regulation of protein processing in phagocytic vesicle
Molecular Function GO:0000146 microfilament motor activity
GO:0003774 motor activity
GO:0003779 actin binding
GO:0005516 calmodulin binding
GO:0016887 ATPase activity
GO:0030898 actin-dependent ATPase activity
GO:0042623 ATPase activity, coupled
GO:0043495 protein anchor
GO:0043531 ADP binding
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0051015 actin filament binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0001725 stress fiber
GO:0001726 ruffle
GO:0001772 immunological synapse
GO:0001931 uropod
GO:0005819 spindle
GO:0005826 actomyosin contractile ring
GO:0005903 brush border
GO:0005913 cell-cell adherens junction
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0005938 cell cortex
GO:0008180 COP9 signalosome
GO:0008305 integrin complex
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0016460 myosin II complex
GO:0030055 cell-substrate junction
GO:0030863 cortical cytoskeleton
GO:0030864 cortical actin cytoskeleton
GO:0031252 cell leading edge
GO:0031254 cell trailing edge
GO:0031594 neuromuscular junction
GO:0032153 cell division site
GO:0032154 cleavage furrow
GO:0032155 cell division site part
GO:0032432 actin filament bundle
GO:0032982 myosin filament
GO:0042641 actomyosin
GO:0043235 receptor complex
GO:0044448 cell cortex part
GO:0070938 contractile ring
GO:0097513 myosin II filament
GO:0097517 contractile actin filament bundle
GO:0097610 cell surface furrow
GO:0098636 protein complex involved in cell adhesion
GO:0098802 plasma membrane receptor complex
GO:0098862 cluster of actin-based cell projections
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04530 Tight junction
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928663: EPHA-mediated growth cone collapse
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-195258: RHO GTPase Effectors
R-HSA-5627117: RHO GTPases Activate ROCKs
R-HSA-5625900: RHO GTPases activate CIT
R-HSA-5627123: RHO GTPases activate PAKs
R-HSA-5625740: RHO GTPases activate PKNs
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-400685: Sema4D in semaphorin signaling
R-HSA-416572: Sema4D induced cell migration and growth-cone collapse
R-HSA-373755: Semaphorin interactions
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
Summary
SymbolMYH9
Namemyosin, heavy chain 9, non-muscle
Aliases NMMHCA; NMHC-II-A; MHA; FTNS; EPSTS; nonmuscle myosin heavy chain II-A; DFNA17; myosin, heavy polypeptide 9, ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYH9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMYH9
Namemyosin, heavy chain 9, non-muscle
Aliases NMMHCA; NMHC-II-A; MHA; FTNS; EPSTS; nonmuscle myosin heavy chain II-A; DFNA17; myosin, heavy polypeptide 9, ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYH9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.54 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMYH9
Namemyosin, heavy chain 9, non-muscle
Aliases NMMHCA; NMHC-II-A; MHA; FTNS; EPSTS; nonmuscle myosin heavy chain II-A; DFNA17; myosin, heavy polypeptide 9, ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYH9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2670.382
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.180.956
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5890.798
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1070.785
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2370.95
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0580.99
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3540.535
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5230.829
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1260.964
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8850.683
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.550.633
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2480.00119
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYH9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.611.1-8.50.299
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.515.4-10.90.541
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYH9
Namemyosin, heavy chain 9, non-muscle
Aliases NMMHCA; NMHC-II-A; MHA; FTNS; EPSTS; nonmuscle myosin heavy chain II-A; DFNA17; myosin, heavy polypeptide 9, ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYH9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYH9
Namemyosin, heavy chain 9, non-muscle
Aliases NMMHCA; NMHC-II-A; MHA; FTNS; EPSTS; nonmuscle myosin heavy chain II-A; DFNA17; myosin, heavy polypeptide 9, ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYH9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYH9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYH9
Namemyosin, heavy chain 9, non-muscle
Aliases NMMHCA; NMHC-II-A; MHA; FTNS; EPSTS; nonmuscle myosin heavy chain II-A; DFNA17; myosin, heavy polypeptide 9, ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYH9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYH9
Namemyosin, heavy chain 9, non-muscle
Aliases NMMHCA; NMHC-II-A; MHA; FTNS; EPSTS; nonmuscle myosin heavy chain II-A; DFNA17; myosin, heavy polypeptide 9, ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYH9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYH9
Namemyosin, heavy chain 9, non-muscle
Aliases NMMHCA; NMHC-II-A; MHA; FTNS; EPSTS; nonmuscle myosin heavy chain II-A; DFNA17; myosin, heavy polypeptide 9, ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYH9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYH9
Namemyosin, heavy chain 9, non-muscle
Aliases NMMHCA; NMHC-II-A; MHA; FTNS; EPSTS; nonmuscle myosin heavy chain II-A; DFNA17; myosin, heavy polypeptide 9, ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYH9 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MYH9.
ID Name Drug Type Targets #Targets
DB11638ArtenimolSmall MoleculeACTG1, ALB, ALDH7A1, ALDOA, ANXA2, ATP5A1, ATP5L, ATP5O, CAST, CCT ......79